{"pmid":32393593,"title":"Recognition and management of respiratory coinfection and secondary bacterial pneumonia in patients with COVID-19.","text":["Recognition and management of respiratory coinfection and secondary bacterial pneumonia in patients with COVID-19.","The pathophysiology of COVID-19 is not fully known. Respiratory infection caused by more than one viral pathogen (viral co-infection) or both viral and bacterial pathogens (combined viral and bacterial pneumonia) have been described. Secondary bacterial pneumonia can follow the initial phase of viral respiratory infection or occur during the recovery phase. No obvious pattern or guidelines exist for viral coinfection, combined viral and bacterial pneumonia, or secondary bacterial pneumonia in the context of SARS-CoV-2. Based on existing clinical data and experience with similar viruses such as influenza and SARS-CoV, the management approach in the context of COVID-19 should, ideally, take into consideration the overall presentation as well as the trajectory of illness.","Cleve Clin J Med","Wu, Chao-Ping","Adhi, Fatima","Highland, Kristin","32393593"],"abstract":["The pathophysiology of COVID-19 is not fully known. Respiratory infection caused by more than one viral pathogen (viral co-infection) or both viral and bacterial pathogens (combined viral and bacterial pneumonia) have been described. Secondary bacterial pneumonia can follow the initial phase of viral respiratory infection or occur during the recovery phase. No obvious pattern or guidelines exist for viral coinfection, combined viral and bacterial pneumonia, or secondary bacterial pneumonia in the context of SARS-CoV-2. Based on existing clinical data and experience with similar viruses such as influenza and SARS-CoV, the management approach in the context of COVID-19 should, ideally, take into consideration the overall presentation as well as the trajectory of illness."],"journal":"Cleve Clin J Med","authors":["Wu, Chao-Ping","Adhi, Fatima","Highland, Kristin"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32393593","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3949/ccjm.87a.ccc015","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666627827811745793,"score":9.490897,"similar":[{"pmid":32448041,"title":"Covid-19 induced superimposed bacterial infection.","text":["Covid-19 induced superimposed bacterial infection.","Viral respiratory infections are very common and they are frequently eliminated from the body without any detrimental consequences. Secondary serious bacterial infection has been an apprehension expressed by health care providers, and this fear has been exacerbated in the era of Covid-19. Several published studies have shown an association between Covid-19 illness and secondary bacterial infection. However, the proposed mechanism by which a virus can develop a secondary bacterial infection is not well delineated. The aim of this commentary is to update the current evidence of the risk of bacterial infection in patients with Covid-19. We present several clinical studies related to the topic as well as a brief review of the potential pathophysiology of secondary infections that could present with Covid-19.","J Biomol Struct Dyn","Hendaus, Mohamed A","Jomha, Fatima A","32448041"],"abstract":["Viral respiratory infections are very common and they are frequently eliminated from the body without any detrimental consequences. Secondary serious bacterial infection has been an apprehension expressed by health care providers, and this fear has been exacerbated in the era of Covid-19. Several published studies have shown an association between Covid-19 illness and secondary bacterial infection. However, the proposed mechanism by which a virus can develop a secondary bacterial infection is not well delineated. The aim of this commentary is to update the current evidence of the risk of bacterial infection in patients with Covid-19. We present several clinical studies related to the topic as well as a brief review of the potential pathophysiology of secondary infections that could present with Covid-19."],"journal":"J Biomol Struct Dyn","authors":["Hendaus, Mohamed A","Jomha, Fatima A"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32448041","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1080/07391102.2020.1772110","keywords":["covid-19","pathogenesis","secondary bacterial infection","studies"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667785213977034752,"score":233.21873},{"pmid":32358954,"pmcid":"PMC7197596","title":"Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing.","text":["Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing.","BACKGROUND: To explore and describe the current literature surrounding bacterial/fungal co-infection in patients with coronavirus infection. METHODS: MEDLINE, EMBASE, and Web of Science were searched using broad based search criteria relating to coronavirus and bacterial co-infection. Articles presenting clinical data for patients with coronavirus infection (defined as SARS-1, MERS, SARS-COV-2, and other coronavirus) and bacterial/fungal co-infection reported in English, Mandarin, or Italian were included. Data describing bacterial/fungal co-infections, treatments, and outcomes were extracted. Secondary analysis of studies reporting antimicrobial prescribing in SARS-COV-2 even in the absence of co-infection was performed. RESULTS: 1007 abstracts were identified. Eighteen full texts reported bacterial/fungal co-infection were included. Most studies did not identify or report bacterial/fungal coinfection (85/140;61%). 9/18 (50%) studies reported on COVID-19, 5/18 (28%) SARS-1, 1/18 (6%) MERS, and 3/18 (17%) other coronavirus.For COVID-19, 62/806 (8%) patients were reported as experiencing bacterial/fungal co-infection during hospital admission. Secondary analysis demonstrated wide use of broad-spectrum antibacterials, despite a paucity of evidence for bacterial coinfection. On secondary analysis, 1450/2010 (72%) of patients reported received antimicrobial therapy. No antimicrobial stewardship interventions were described.For non-COVID-19 cases bacterial/fungal co-infection was reported in 89/815 (11%) of patients. Broad-spectrum antibiotic use was reported. CONCLUSIONS: Despite frequent prescription of broad-spectrum empirical antimicrobials in patients with coronavirus associated respiratory infections, there is a paucity of data to support the association with respiratory bacterial/fungal co-infection. Generation of prospective evidence to support development of antimicrobial policy and appropriate stewardship interventions specific for the COVID-19 pandemic are urgently required.","Clin Infect Dis","Rawson, Timothy M","Moore, Luke S P","Zhu, Nina","Ranganathan, Nishanthy","Skolimowska, Keira","Gilchrist, Mark","Satta, Giovanni","Cooke, Graham","Holmes, Alison","32358954"],"abstract":["BACKGROUND: To explore and describe the current literature surrounding bacterial/fungal co-infection in patients with coronavirus infection. METHODS: MEDLINE, EMBASE, and Web of Science were searched using broad based search criteria relating to coronavirus and bacterial co-infection. Articles presenting clinical data for patients with coronavirus infection (defined as SARS-1, MERS, SARS-COV-2, and other coronavirus) and bacterial/fungal co-infection reported in English, Mandarin, or Italian were included. Data describing bacterial/fungal co-infections, treatments, and outcomes were extracted. Secondary analysis of studies reporting antimicrobial prescribing in SARS-COV-2 even in the absence of co-infection was performed. RESULTS: 1007 abstracts were identified. Eighteen full texts reported bacterial/fungal co-infection were included. Most studies did not identify or report bacterial/fungal coinfection (85/140;61%). 9/18 (50%) studies reported on COVID-19, 5/18 (28%) SARS-1, 1/18 (6%) MERS, and 3/18 (17%) other coronavirus.For COVID-19, 62/806 (8%) patients were reported as experiencing bacterial/fungal co-infection during hospital admission. Secondary analysis demonstrated wide use of broad-spectrum antibacterials, despite a paucity of evidence for bacterial coinfection. On secondary analysis, 1450/2010 (72%) of patients reported received antimicrobial therapy. No antimicrobial stewardship interventions were described.For non-COVID-19 cases bacterial/fungal co-infection was reported in 89/815 (11%) of patients. Broad-spectrum antibiotic use was reported. CONCLUSIONS: Despite frequent prescription of broad-spectrum empirical antimicrobials in patients with coronavirus associated respiratory infections, there is a paucity of data to support the association with respiratory bacterial/fungal co-infection. Generation of prospective evidence to support development of antimicrobial policy and appropriate stewardship interventions specific for the COVID-19 pandemic are urgently required."],"journal":"Clin Infect Dis","authors":["Rawson, Timothy M","Moore, Luke S P","Zhu, Nina","Ranganathan, Nishanthy","Skolimowska, Keira","Gilchrist, Mark","Satta, Giovanni","Cooke, Graham","Holmes, Alison"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32358954","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1093/cid/ciaa530","keywords":["sars-cov-2","antimicrobial resistance","antimicrobial stewardship"],"locations":["Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495313248256,"score":224.46362},{"pmid":32500854,"title":"Primary Respiratory Bacterial Coinfections in Patients with COVID-19.","text":["Primary Respiratory Bacterial Coinfections in Patients with COVID-19.","Primary Respiratory Bacterial Coinfections in Patients with COVID-19.","Am J Trop Med Hyg","Chaudhary, Waqas Ahmed","Chong, Pui Lin","Mani, Babu Ivan","Asli, Rosmonaliza","Momin, Riamiza Natalie","Abdullah, Muhammad Syafiq","Chong, Vui Heng","32500854"],"abstract":["Primary Respiratory Bacterial Coinfections in Patients with COVID-19."],"journal":"Am J Trop Med Hyg","authors":["Chaudhary, Waqas Ahmed","Chong, Pui Lin","Mani, Babu Ivan","Asli, Rosmonaliza","Momin, Riamiza Natalie","Abdullah, Muhammad Syafiq","Chong, Vui Heng"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32500854","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.4269/ajtmh.20-0498","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1668890966267789313,"score":210.52586},{"pmid":32473235,"title":"Co-infections in people with COVID-19: a systematic review and meta-analysis.","text":["Co-infections in people with COVID-19: a systematic review and meta-analysis.","OBJECTIVES: In previous influenza pandemics, bacterial co-infections have been a major cause of mortality. We aimed to evaluate the burden of co-infections in patients with COVID-19. METHODS: We systematically searched Embase, Medline, Cochrane Library, LILACS and CINAHL for eligible studies published from 1 January 2020 to 17 April 2020. We included patients of all ages, in all settings. The main outcome was the proportion of patients with a bacterial, fungal or viral co-infection. . RESULTS: Thirty studies including 3834 patients were included. Overall, 7% of hospitalised COVID-19 patients had a bacterial co-infection (95% CI 3-12%, n=2183, I(2)=922%). A higher proportion of ICU patients had bacterial co-infections than patients in mixed ward/ICU settings (14%, 95% CI 5-26, I(2)=747% versus 4%, 95% CI 1-9, I(2)= 917%). The commonest bacteria were Mycoplasma pneumonia, Pseudomonas aeruginosa and Haemophilus influenzae. The pooled proportion with a viral co-infection was 3% (95% CI 1-6, n=1014, I(2)=623%), with Respiratory Syncytial Virus and influenza A the commonest. Three studies reported fungal co-infections. CONCLUSIONS: A low proportion of COVID-19 patients have a bacterial co-infection; less than in previous influenza pandemics. These findings do not support the routine use of antibiotics in the management of confirmed COVID-19 infection.","J Infect","Lansbury, Louise","Lim, Benjamin","Baskaran, Vadsala","Lim, Wei Shen","32473235"],"abstract":["OBJECTIVES: In previous influenza pandemics, bacterial co-infections have been a major cause of mortality. We aimed to evaluate the burden of co-infections in patients with COVID-19. METHODS: We systematically searched Embase, Medline, Cochrane Library, LILACS and CINAHL for eligible studies published from 1 January 2020 to 17 April 2020. We included patients of all ages, in all settings. The main outcome was the proportion of patients with a bacterial, fungal or viral co-infection. . RESULTS: Thirty studies including 3834 patients were included. Overall, 7% of hospitalised COVID-19 patients had a bacterial co-infection (95% CI 3-12%, n=2183, I(2)=922%). A higher proportion of ICU patients had bacterial co-infections than patients in mixed ward/ICU settings (14%, 95% CI 5-26, I(2)=747% versus 4%, 95% CI 1-9, I(2)= 917%). The commonest bacteria were Mycoplasma pneumonia, Pseudomonas aeruginosa and Haemophilus influenzae. The pooled proportion with a viral co-infection was 3% (95% CI 1-6, n=1014, I(2)=623%), with Respiratory Syncytial Virus and influenza A the commonest. Three studies reported fungal co-infections. CONCLUSIONS: A low proportion of COVID-19 patients have a bacterial co-infection; less than in previous influenza pandemics. These findings do not support the routine use of antibiotics in the management of confirmed COVID-19 infection."],"journal":"J Infect","authors":["Lansbury, Louise","Lim, Benjamin","Baskaran, Vadsala","Lim, Wei Shen"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32473235","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.jinf.2020.05.046","keywords":["covid-19","coinfection","coronavirus","meta-analysis"],"locations":["Mycoplasma","Haemophilus"],"topics":["Diagnosis"],"weight":1,"_version_":1668255193412665345,"score":192.85648},{"pmid":32408156,"pmcid":"PMC7213959","title":"Co-infection with respiratory pathogens among COVID-2019 cases.","text":["Co-infection with respiratory pathogens among COVID-2019 cases.","Accumulating evidence shows that microbial co-infection increases the risk of disease severity in humans. There have been few studies about SARS-CoV-2 co-infection with other pathogens. In this retrospective study, 257 laboratory-confirmed COVID-19 patients in Jiangsu Province were enrolled from January 22 to February 2, 2020. They were re-confirmed by real-time RT-PCR and tested for 39 respiratory pathogens. In total, 24 respiratory pathogens were found among the patients, and 242 (94.2 %) patients were co-infected with one or more pathogens. Bacterial co-infections were dominant in all COVID-19 patients, Streptococcus pneumoniae was the most common, followed by Klebsiella pneumoniae and Haemophilus influenzae. The highest and lowest rates of co-infections were found in patients aged 15-44 and below 15, respectively. Most co-infections occurred within 1-4 days of onset of COVID-19 disease. In addition, the proportion of viral co-infections, fungal co-infections and bacterial-fungal co-infections were the highest severe COVID-19 cases. These results will provide a helpful reference for diagnosis and clinical treatment of COVID-19 patients.","Virus Res","Zhu, Xiaojuan","Ge, Yiyue","Wu, Tao","Zhao, Kangchen","Chen, Yin","Wu, Bin","Zhu, Fengcai","Zhu, Baoli","Cui, Lunbiao","32408156"],"abstract":["Accumulating evidence shows that microbial co-infection increases the risk of disease severity in humans. There have been few studies about SARS-CoV-2 co-infection with other pathogens. In this retrospective study, 257 laboratory-confirmed COVID-19 patients in Jiangsu Province were enrolled from January 22 to February 2, 2020. They were re-confirmed by real-time RT-PCR and tested for 39 respiratory pathogens. In total, 24 respiratory pathogens were found among the patients, and 242 (94.2 %) patients were co-infected with one or more pathogens. Bacterial co-infections were dominant in all COVID-19 patients, Streptococcus pneumoniae was the most common, followed by Klebsiella pneumoniae and Haemophilus influenzae. The highest and lowest rates of co-infections were found in patients aged 15-44 and below 15, respectively. Most co-infections occurred within 1-4 days of onset of COVID-19 disease. In addition, the proportion of viral co-infections, fungal co-infections and bacterial-fungal co-infections were the highest severe COVID-19 cases. These results will provide a helpful reference for diagnosis and clinical treatment of COVID-19 patients."],"journal":"Virus Res","authors":["Zhu, Xiaojuan","Ge, Yiyue","Wu, Tao","Zhao, Kangchen","Chen, Yin","Wu, Bin","Zhu, Fengcai","Zhu, Baoli","Cui, Lunbiao"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32408156","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.virusres.2020.198005","keywords":["covid-19","co-infection","rt-pcr","sars-cov-2"],"locations":["Jiangsu"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666950579783467008,"score":192.11182}]}